Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Stock analysts at B. Riley lowered their FY2024 earnings per share (EPS) estimates for shares of Viridian Therapeutics in a research note issued to investors on Monday, November 18th. B. Riley analyst K. Patel now forecasts that the company will post earnings per share of ($4.01) for the year, down from their previous estimate of ($3.80). The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.01) per share. B. Riley also issued estimates for Viridian Therapeutics' FY2025 earnings at ($4.82) EPS, FY2026 earnings at ($4.91) EPS, FY2027 earnings at ($3.67) EPS and FY2028 earnings at ($2.23) EPS.
Several other research analysts also recently issued reports on the company. HC Wainwright upped their price objective on Viridian Therapeutics from $27.00 to $34.00 and gave the stock a "buy" rating in a report on Thursday, November 14th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $44.00 target price on shares of Viridian Therapeutics in a report on Thursday, September 19th. BTIG Research raised their price objective on Viridian Therapeutics from $56.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, September 26th. The Goldman Sachs Group lifted their price target on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, September 12th. Finally, Oppenheimer restated an "outperform" rating and issued a $28.00 target price (down previously from $31.00) on shares of Viridian Therapeutics in a research note on Monday, August 12th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Viridian Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $36.33.
Check Out Our Latest Analysis on VRDN
Viridian Therapeutics Stock Performance
Shares of NASDAQ:VRDN traded up $0.33 during trading on Wednesday, hitting $20.57. 150,421 shares of the stock were exchanged, compared to its average volume of 1,117,240. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The company's fifty day simple moving average is $22.79 and its 200-day simple moving average is $17.09. Viridian Therapeutics has a 1-year low of $11.40 and a 1-year high of $27.20. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of -4.70 and a beta of 1.10.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.04). Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.08 million.
Insider Buying and Selling
In related news, CEO Stephen F. Mahoney purchased 21,400 shares of the stock in a transaction dated Friday, September 27th. The stock was purchased at an average price of $23.33 per share, with a total value of $499,262.00. Following the transaction, the chief executive officer now directly owns 21,400 shares in the company, valued at $499,262. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Fairmount Funds Management Llc purchased 1,600,000 shares of Viridian Therapeutics stock in a transaction dated Friday, September 13th. The stock was bought at an average price of $18.75 per share, with a total value of $30,000,000.00. Following the completion of the purchase, the director now directly owns 3,445,813 shares of the company's stock, valued at approximately $64,608,993.75. This trade represents a 86.68 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 1,626,400 shares of company stock worth $30,616,312 in the last quarter. 0.65% of the stock is owned by insiders.
Institutional Investors Weigh In On Viridian Therapeutics
Large investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. increased its position in Viridian Therapeutics by 19.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company's stock valued at $87,000 after purchasing an additional 799 shares during the period. Quest Partners LLC lifted its stake in Viridian Therapeutics by 344.0% in the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company's stock worth $79,000 after purchasing an additional 4,692 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Viridian Therapeutics during the third quarter worth $149,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Viridian Therapeutics in the 3rd quarter valued at about $208,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Viridian Therapeutics by 24.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company's stock worth $156,000 after buying an additional 2,359 shares during the last quarter.
About Viridian Therapeutics
(
Get Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Further Reading
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.